Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | PKM | P14618 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11001844 | 0.80 | MEN1 (0.41) | MAPTCYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL11189550 | 0.78 | ALDH1A1 (0.37) | MAPTCYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL750585 | 0.78 | MAPT (0.46) | MAPTCYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL2722102 | 0.74 | PDE4A (0.46) | MAPTCYP1A2ALDH1A1KMT2AKDM4E | |
| SCHEMBL15689263 | 0.72 | HSP90AB1 (0.40) | MAPTCYP1A2CYP2C9CYP2C19HSP90AB1 | |
| SCHEMBL21711151 | 0.72 | CYP1A2 (0.48) | MAPTCYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL2721693 | 0.71 | KMT2A (0.46) | MAPTCYP2C19ALDH1A1MEN1KMT2A | |
| SCHEMBL3596376 | 0.69 | L3MBTL1 (0.32) | — | |
| SCHEMBL118222 | 0.68 | MAPT (0.39) | MAPTCYP1A2CYP2C9CYP2C19HSP90AB1 | |
| SCHEMBL115419 | 0.68 | MAPT (0.39) | MAPTCYP1A2CYP2C9CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-4612375-A | Substituted 4-hydrazino-pyrimides as intermediates for triazolo [4,3-c]pyrimidines | RIKER LABORATORIES, INC. (US) | 1986-09-16 | — | — | US | disclosed |
| US-4532242-A | Bronchodilator agents | RIKER LABORATORIES, INC. (US) | 1985-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | MAPT 3169/4885CYP1A2 2264/4885CYP2C9 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.